<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492622</url>
  </required_header>
  <id_info>
    <org_study_id>014.07</org_study_id>
    <nct_id>NCT00492622</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis</brief_title>
  <official_title>Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the blood drug levels of two prescribed medications,
      immediate-release omeprazole 40 mg powder and delayed-release omeprazole 40 mg capsule to
      determine which drug is better absorbed in patients with a slow stomach emptying
      (gastroparesis). Delayed-release omeprazole has a protective coating to prevent the drug
      omeprazole from being neutralized by stomach acid. Immediate-release omeprazole has sodium
      bicarbonate (antacid) which neutralizes the stomach acid, eliminating the need for a
      protective coating. Immediate-release omeprazole suspension may have a more rapid
      pharmacokinetic profile and greater overall drug absorption in gastroparesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Immediate-release omeprazole suspension may have a more rapid pharmacokinetic
      profile and greater overall drug absorption in gastroparesis. This will result in shorter
      time to maximal drug concentration, greater maximal concentration, and greater total area
      under the curve of the concentration vs. time plot.

      Primary Objective: To compare the pharmacokinetics of omeprazole between immediate-release
      suspension and delayed-release capsules in patients with heartburn associated with
      gastroparesis.

      Study design: randomized, open-labeled, crossover treatment for 7 days with 10-14 days
      washout. Pharmacokinetic studies will be performed after 7 days on study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Maximal Omeprazole Concentration (Tmax)</measure>
    <time_frame>10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240 and 300 min after the study drug was ingested on day 7 of treatment</time_frame>
    <description>Time to max concentration for Immediate release vs. Delayed release omeprazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Concentration of Omerazole</measure>
    <time_frame>10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240 and 300 min after the study drug was ingested on day 7 of treatment</time_frame>
    <description>Maximal concentration of immediate-release vs. delayed-release omeprazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve for Omeprazole Plasma Concentration</measure>
    <time_frame>0 to 5 hrs after the study drug was ingested on treatment day 7</time_frame>
    <description>The area under the curve for omeprazole concentration-time curve for immediate release and delayed release omeprazole.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Immediate-release omeprazole release first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects receive immediate release omeprazole for 7 days then delayed release for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed-release omeprazole first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects receive delayed release omeprazole for 7 days then immediate release for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate-release omeprazole</intervention_name>
    <description>Immediate-release omeprazole 40 mg qam for 7 days</description>
    <arm_group_label>Immediate-release omeprazole release first</arm_group_label>
    <arm_group_label>Delayed-release omeprazole first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delayed-release omeprazole</intervention_name>
    <description>Delayed-release omeprazole 40 mg qam for 7 days</description>
    <arm_group_label>Immediate-release omeprazole release first</arm_group_label>
    <arm_group_label>Delayed-release omeprazole first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms of heartburn &gt;2 days per week off antireflux therapy, defined by &quot;a burning
             feeling rising from the stomach or lower chest up towards the neck&quot;

          -  Symptoms of gastroparesis &gt;1 month in duration, defined by nausea, vomiting, bloating,
             dyspepsia, early satiety, or effortless regurgitation.

          -  Prior abnormal 4-hour gastric emptying scan within the past 3 years

        Exclusion Criteria:

          -  History of esophageal or gastric surgery

          -  Severe gastroparesis with any of the following: vomiting with dehydration requiring IV
             hydration, hospitalization, weight loss &gt;10 % pre-illness weight, requiring feeding
             jejunostomy tubes

          -  Presence of gastric electrical stimulator

          -  Symptoms of retching with vomiting more than 2 days per week

          -  Diagnosis of diabetes

          -  Disorders of small bowel motility (such as pseudo-obstruction or dumping syndrome)

          -  Disorders of small bowel absorption

          -  Diagnosis of gastric outlet, small bowel or colon mechanical obstruction

          -  Diagnosis of acid hypersecretory syndrome

          -  Disorders affecting proton pump inhibitor metabolism (such as liver failure)

          -  Known allergy or side effects to proton pump inhibitor

          -  Non-ambulatory patients: bed-ridden, nursing home resident, etc.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Wo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Health Center, University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wo JM, Eversmann J, Mann S. Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis. Aliment Pharmacol Ther. 2010 Feb 15;31(4):516-22. doi: 10.1111/j.1365-2036.2009.04203.x. Epub 2009 Nov 19.</citation>
    <PMID>19925497</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>June 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2017</results_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroparesis</keyword>
  <keyword>Gastroesophageal reflux disease</keyword>
  <keyword>heartburn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>All participants were randomized to receive all formulations so baseline measures are reported for all participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12">all subjects received the immediate release formulation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximal Omeprazole Concentration (Tmax)</title>
        <description>Time to max concentration for Immediate release vs. Delayed release omeprazole</description>
        <time_frame>10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240 and 300 min after the study drug was ingested on day 7 of treatment</time_frame>
        <population>All subjects were included regardless of which formulation they received first.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants Immediate Release Arm</title>
            <description>Immediate-release omeprazole: Immediate-release omeprazole 40 mg qam for 7 days</description>
          </group>
          <group group_id="O2">
            <title>All Study Subjects Delayed Release Arm</title>
            <description>Delayed-release omeprazole: Delayed-release omeprazole 40 mg qam for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximal Omeprazole Concentration (Tmax)</title>
          <description>Time to max concentration for Immediate release vs. Delayed release omeprazole</description>
          <population>All subjects were included regardless of which formulation they received first.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="11"/>
                    <measurement group_id="O2" value="97" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary study objective was to compare the pharmacokinetics of omeprazole between IR and DR omeprazole in patients with GERD associated with gastroparesis.</non_inferiority_desc>
            <p_value>&lt; 0.01</p_value>
            <p_value_desc>&lt;0.01 is used for determining the level of significance.</p_value_desc>
            <method>paired t-tests</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal Concentration of Omerazole</title>
        <description>Maximal concentration of immediate-release vs. delayed-release omeprazole</description>
        <time_frame>10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240 and 300 min after the study drug was ingested on day 7 of treatment</time_frame>
        <population>All subjects were included, regardless of which formulation they received first.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants Immediate Release Arm</title>
            <description>Immediate-release omeprazole concentration: Immediate-release omeprazole 40 mg qam for 7 days</description>
          </group>
          <group group_id="O2">
            <title>All Study Subjects Delayed Release Arm</title>
            <description>Delayed-release omeprazole concentration: Delayed-release omeprazole 40 mg qam for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Concentration of Omerazole</title>
          <description>Maximal concentration of immediate-release vs. delayed-release omeprazole</description>
          <population>All subjects were included, regardless of which formulation they received first.</population>
          <units>ng/mL plasma</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1979" spread="832"/>
                    <measurement group_id="O2" value="1625" spread="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary study objective was to compare the pharmacokinetics of omeprazole between IR and DR omeprazole in patients with GERD associated with gastroparesis.</non_inferiority_desc>
            <other_analysis_desc>P&lt;0.05 was used as the level of significance with ANOVA for this endpoint.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve for Omeprazole Plasma Concentration</title>
        <description>The area under the curve for omeprazole concentration-time curve for immediate release and delayed release omeprazole.</description>
        <time_frame>0 to 5 hrs after the study drug was ingested on treatment day 7</time_frame>
        <population>the AUC for each formulation were combined regardless of order given</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants Immediate Release Arm</title>
            <description>Immediate-release omeprazole: Immediate-release omeprazole 40 mg qam for 7 days</description>
          </group>
          <group group_id="O2">
            <title>All Study Subjects Delayed Release Arm</title>
            <description>Delayed-release omeprazole: Delayed-release omeprazole 40 mg qam for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for Omeprazole Plasma Concentration</title>
          <description>The area under the curve for omeprazole concentration-time curve for immediate release and delayed release omeprazole.</description>
          <population>the AUC for each formulation were combined regardless of order given</population>
          <units>mg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3842" spread="1618"/>
                    <measurement group_id="O2" value="3745" spread="2386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary study objective was to compare the pharmacokinetics of omeprazole between IR and DR omeprazole in patients with GERD associated with gastroparesis.</non_inferiority_desc>
            <p_value>0.95</p_value>
            <p_value_desc>An analysis of variance model was used to compare AUC between IR and DR omeprazole using the natural logarithmic transformation. The model included the following factors: treatment, period, sequence and patient nested within the sequence.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Immediate Release Fomeprazole</title>
          <description>subjects received immediate release for 7 days then delayed release for 7 days
Immediate-release omeprazole: Immediate-release omeprazole 40 mg qam for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Delayed Release Omeprazole</title>
          <description>subjects receive delayed release for 7 days then immediate release for 7 days
Delayed-release omeprazole: Delayed-release omeprazole 40 mg qam for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy Alsip</name_or_title>
      <organization>University Louisville</organization>
      <phone>502-852-2905</phone>
      <email>nancy.alsip@louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

